Provided by Tiger Trade Technology Pte. Ltd.

Indaptus Therapeutics, Inc.

1.80
+0.250016.13%
Post-market: 1.76-0.0400-2.22%17:11 EST
Volume:48.87K
Turnover:85.70K
Market Cap:4.04M
PE:-0.06
High:1.90
Open:1.52
Low:1.52
Close:1.55
52wk High:47.60
52wk Low:1.52
Shares:2.24M
Float Shares:985.10K
Volume Ratio:1.23
T/O Rate:4.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-29.0300
EPS(LYR):-44.9582
ROE:-317.98%
ROA:-131.38%
PB:0.88
PE(LYR):-0.04

Loading ...

Indaptus Therapeutics Cuts Executive Officer Salaries to $60,000 Per Year

Reuters
·
Jan 21

Indaptus Therapeutics Files Initial Statement of Beneficial Ownership for Director David Natan

Reuters
·
Jan 13

Indaptus Therapeutics Appoints David Natan to Board of Directors

Reuters
·
Jan 09

Indaptus Therapeutics Inc. Announces Date for Special Stockholder Meeting

Reuters
·
Jan 09

BRIEF-Indupro Therapeutics Announces Strategic Collaboration With Lilly

Reuters
·
Jan 08

Indaptus Therapeutics Board Members Resign Pending Approval of New Nominees

Reuters
·
Jan 03

Indaptus Therapeutics Inc - David E. Lazar Appointed Co-CEO and Chairman of Board

THOMSON REUTERS
·
Dec 29, 2025

Indaptus Enters Into $6 Million Securities Purchase Agreement With Investor David E. Lazar

THOMSON REUTERS
·
Dec 29, 2025

Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading?

Benzinga_recent_news
·
Dec 24, 2025

Indaptus Therapeutics Files Initial Beneficial Ownership Statement for Director Avraham Ben-Tzvi

Reuters
·
Dec 24, 2025

Indaptus' Stock Up After Lazar Agrees to Buy 1M Shares, Become Co-CEO and Chair

Dow Jones
·
Dec 24, 2025

BRIEF-Indaptus Therapeutics Inc - Appointed David Lazar As The Co-Chief Executive Officer

Reuters
·
Dec 24, 2025

Indaptus Therapeutics Inc - Appointed David Lazar as the Co-Chief Executive Officer

THOMSON REUTERS
·
Dec 24, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (INDP) and Fate Therapeutics (FATE)

TIPRANKS
·
Nov 14, 2025

Indaptus Therapeutics Q3 profit beats estimates

Reuters
·
Nov 12, 2025

Indaptus Therapeutics posts third quarter net loss of $2.98 per share

Reuters
·
Nov 12, 2025

Rpt-Indaptus Therapeutics Q3 EPS USD -2.98

THOMSON REUTERS
·
Nov 12, 2025

Investors Await Key Jobs Data as US Futures Mixed in Friday's Premarket

MT Newswires Live
·
Sep 05, 2025

Indaptus Therapeutics Announces Promising Updates on Decoy20 and Tislelizumab Combination Therapy in Ongoing Clinical Trial

Reuters
·
Sep 05, 2025

Indaptus Therapeutics Inc - Decoy20 Monotherapy Induces Partial Response in Cancer Patient

THOMSON REUTERS
·
Sep 05, 2025